hes family bHLH transcription factor 1Genealiases: HES-1 · HHL · HRY · bHLHb39
Q-omics provides the consensus-scored HES1 profile across patient tissues and cancer cell-line models. HES1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HES1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, HES1 protein abundance shows 32,474 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KICH, and PDAC as cancer lineages where HES1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HES1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HES1 survival associations across molecular data types. HES1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HES1 RNA expression–survival associations across cancer types. High HES1 expression shows unfavorable associations in ACC, UVM, LGG and PAAD, but favorable associations in BLCA and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HES1 RNA expression.
This table summarizes HES1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HES1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HES1 shows lower tumor expression in KICH and KIRC and higher tumor expression in BLCA, LUSC, LUAD and STAD. The KICH box plot shows higher HES1 RNA expression in normal versus tumor tissue (log2 FC = −3.437, t-test p < 0.001).
This table shows molecular features associated with HES1 in patient tissues and cancer cell lines. In patient samples, HES1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HES1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
